Vasomotor Rhinitis (Idiopathic Nonallergic Rhinitis)

Definition and Terminology

• Cummings Otolaryngology Head and Neck Surgery
• Textbook of Family Medicine 9e

Classification of Nonallergic Rhinitis (Context)

• Cummings Otolaryngology, Box 39.1

Pathophysiology

1. Autonomic dysregulation - historically, the primary explanation. Involves either excessive parasympathetic activity or reduced sympathetic tone, causing vasodilation of submucosal venous sinusoids and increased seromucous secretion from nasal glands.
2. Nasal hyperreactivity - some IR patients demonstrate hyperreactivity to cold air and histamine, suggesting overlap with NARES and even allergic rhinitis on a continuum.
3. Neurogenic mechanisms - dysregulation of afferent nociceptive pathways via the TRPV1 (transient receptor potential vanilloid 1) receptor has been implicated. This receptor is overexpressed in IR patients and responds to temperature, irritants, and chemical stimuli.
4. Possible low-grade inflammation - immunohistochemical studies have found mast cells, eosinophils, and IgE-positive cells in nasal mucosa of some VMR patients, though other studies found no inflammatory cell infiltrate, suggesting the condition may be noninflammatory in many cases.
5. Conversion to allergic rhinitis - importantly, up to one-quarter of IR patients may convert to positive allergy testing over time, suggesting a dynamic relationship.

• Cummings Otolaryngology; Textbook of Family Medicine 9e

Clinical Features

• Perennial or episodic nasal congestion and rhinorrhea (primary symptoms)
• Sneezing (less prominent than in allergic rhinitis)
• Absence of significant pruritus or conjunctival symptoms (differentiates from allergic rhinitis)

• Temperature changes (especially cold, dry air)
• Barometric pressure changes
• Strong odors (perfumes, cologne, incense, cleaning products)
• Cigarette smoke
• Alcohol
• Exercise
• Emotional stress
• Symptoms may also arise spontaneously with no identifiable trigger

• Often perennial (unlike seasonal allergic rhinitis)
• Can affect any age but onset often in adulthood
• Associated with autonomic imbalance conditions (GERD, etc.)

Diagnosis

• Allergy skin tests: negative
• Nasal smear: <25% eosinophils (rules out NARES)
• No evidence of infection, structural cause, or systemic disease
• Failure to fully respond to topical or systemic corticosteroids alone can support the diagnosis

• Allergic rhinitis (skin prick test / specific IgE)
• NARES (nasal eosinophil count)
• Drug-induced rhinitis (medication history)
• Hormonal rhinitis
• Rhinitis medicamentosa
• Structural causes (deviated septum, turbinate hypertrophy, adenoid hypertrophy, nasal polyps)

Treatment

Step 1: Trigger Avoidance

Step 2: Medical Management

• Mainstay for NARES; also beneficial in IR, though weather-sensitive IR may respond poorly
• Beclomethasone propionate and fluticasone propionate aqueous are FDA-approved for NAR specifically
• Side effects: nasal dryness, epistaxis, headache

• Azelastine nasal spray: FDA-approved for VMR/NAR; works via H1-receptor antagonism plus anti-inflammatory effects (inhibits leukotrienes, kinins, cytokines; modulates TRPV1)
• Olopatadine: comparable efficacy to azelastine but not FDA-approved for NAR
• Combination therapy (azelastine + fluticasone) is superior to monotherapy for chronic rhinitis
• Oral antihistamines have limited role in pure IR (more useful in NARES for sneezing/itching)

• Ipratropium bromide 0.03%-0.06% (Atrovent nasal): directly targets parasympathetic-driven watery rhinorrhea; particularly effective in gustatory and idiopathic subtypes

• Hypertonic (3%) saline irrigation improves nasal symptoms and reduces mucin levels; useful adjunct

• Useful for congestion; caution regarding rebound if topical decongestants are used chronically

• Emerging therapy; acts via TRPV1-mediated atrophy of afferent nociceptive pathways
• Cochrane review supports improvement in nasal symptoms up to 36 weeks post-treatment
• Limited by mucosal irritation/patient tolerance

Step 3: Surgical Management (refractory cases)

• For hypertrophy causing obstruction; mucosal-sparing techniques preferred (radiofrequency, submucosal microdebrider, lateral outfracture)
• Complete resection is avoided (risk of empty nose syndrome)

• Into inferior/middle turbinate heads; reduces rhinorrhea via anticholinergic effect
• Effect is temporary (~12 weeks); does not address non-rhinorrhea symptoms

• Disrupts autonomic (parasympathetic secretomotor) supply to the nasal cavity
• Success rate up to 91% endoscopically
• Risk: dry eyes or palate numbness from inadvertent injury to lacrimal/palatal nerve branches

• More targeted: transects postganglionic parasympathetic fibers at the sphenopalatine foramen
• Avoids injury to lacrimal gland and palatal nerve (advantage over vidian neurectomy)
• Office-based cryoablation of PNN (nitrous oxide, 1 minute) is an emerging in-office option with improvement up to 1 year
• Cummings Otolaryngology Head and Neck Surgery (Chapter 39)

Key Distinguishing Points

Recent Evidence Note

Vasomotor Rhinitis (Idiopathic Rhinitis)

Terminology and Definition

• Cummings Otolaryngology Head and Neck Surgery

Classification of Nonallergic Rhinitis

Pathophysiology

1. Autonomic dysregulation - the classic explanation. Involves excessive parasympathetic tone or reduced sympathetic tone, causing vasodilation of submucosal venous sinusoids and hypersecretion from nasal seromucous glands. This is analogous to functional bowel disease (irritable bowel syndrome).
2. Nasal hyperreactivity via TRPV1 - TRPV1 (transient receptor potential vanilloid 1) receptor overexpression in the nasal mucosa leads to exaggerated responses to temperature, chemical, and mechanical stimuli. This is a key neurogenic mechanism.
3. Continuum with NARES - some IR patients show nasal hyperreactivity to both cold air and histamine, suggesting overlap across NAR subtypes rather than a clean boundary.
4. Possible conversion to allergic rhinitis - up to one-quarter of IR patients convert to positive allergy testing on longitudinal follow-up, suggesting a dynamic rather than fixed diagnosis.
5. Variable inflammation - some histological studies have found mast cells, eosinophils, and IgE-positive cells in nasal mucosa; others show no inflammatory infiltrate, reinforcing that noninflammatory pathways drive a significant proportion of cases.

• Cummings Otolaryngology; Murray & Nadel's Textbook of Respiratory Medicine

Clinical Features

• Perennial or episodic nasal congestion and rhinorrhea (watery or clear)
• Sneezing (less prominent than in allergic rhinitis)
• Absence of significant nasal/ocular pruritus (helps distinguish from allergic rhinitis)
• Symptoms may occur spontaneously without any identifiable trigger

• More common in older adults (senile/gustatory overlap)
• Perennial pattern (unlike seasonal allergic rhinitis)
• Associated with autonomic disorders and GERD

Diagnosis

• Allergic rhinitis (IgE-mediated)
• NARES (eosinophilic, negative IgE)
• Drug-induced rhinitis
• Rhinitis medicamentosa
• Hormonal rhinitis (especially in pregnancy)
• Structural causes (septal deviation, turbinate hypertrophy, polyps)
• Systemic causes (GPA, sarcoidosis, Sjögren syndrome)

Treatment

Step 1 - Trigger Identification and Avoidance

• Take a careful history to identify specific triggers
• Advise smoking cessation; discontinue offending medications
• Use protective masks for occupational/environmental exposures
• Avoidance of perfumes, cleaning products; modify diet if gustatory triggers present
• In practice, complete avoidance is often impossible - medical therapy is then needed

Step 2 - Medical Management

• First-line for most NAR subtypes, including IR
• Beclomethasone propionate and fluticasone propionate aqueous are the only FDA-approved INS specifically for NAR
• Suppress mast cells, eosinophils, basophils, and local inflammation
• Note: weather-sensitive IR may respond poorly to INS, reflecting non-inflammatory pathways
• Side effects: nasal dryness, epistaxis, throat dryness, headache

• Azelastine nasal spray - FDA-approved for VMR/NAR; double-blind RCT confirmed improvement in VMR symptom scores vs. placebo
  • Mechanism: H1-receptor antagonism + inhibits leukotrienes/kinins/cytokines + modulates TRPV1 activity
  • Side effect: persistent bitter taste (can be masked with sucralose)
• Olopatadine - comparable efficacy to azelastine in short-term IR treatment, but not FDA-approved for NAR
• Combination (azelastine + fluticasone) is superior to either agent alone for chronic rhinitis

• Ipratropium bromide 0.03-0.06% (Atrovent nasal spray)
• Targets parasympathetic-driven hypersecretion directly; particularly effective in gustatory and idiopathic subtypes with prominent watery rhinorrhea
• Also especially useful in senile rhinitis and elderly patients

• Hypertonic (3%) saline lavage improves symptom scores and reduces mucin production in IR patients; useful adjunct to pharmacotherapy

• Emerging option for refractory IR
• Mechanism: TRPV1-mediated atrophy of afferent nociceptive signaling
• Cochrane review: improved nasal symptoms up to 36 weeks post-treatment
• Limited by nasal mucosal irritation and poor tolerability

Step 3 - Surgical Management (refractory to medical therapy)

• For hypertrophy contributing to obstruction and nasal hyperreactivity
• Techniques: radiofrequency ablation, submucosal microdebrider, electrocautery, cryotherapy, lateral outfracture
• Mucosal-sparing techniques preferred - complete turbinectomy risks "empty nose syndrome" (paradoxical obstruction)

• Injected into inferior and middle turbinate heads
• Reduces rhinorrhea via anticholinergic effect on nasal secretory glands
• Duration limited to ~12 weeks; does not address nasal obstruction or other non-rhinorrhea symptoms

• Disrupts the entire parasympathetic supply to the nasal cavity (and lacrimal/palatal glands)
• Endoscopic approach: success rate up to 91%
• Complications: dry eye and palate numbness from collateral injury to lacrimal and palatal preganglionic fibers - typically temporary but occasionally permanent, reducing surgical acceptability

• Targets postganglionic parasympathetic fibers at the sphenopalatine foramen
• Because it is distal to the sphenopalatine ganglion, it spares lacrimal and palatal innervation - avoids dry eye risk
• In-office cryoablation (nitrous oxide applied to the posterior middle meatus, 1 minute, under local anesthesia) - pilot data shows improvement up to 1 year post-treatment; growing minimally invasive option
• Cummings Otolaryngology Head and Neck Surgery, Chapter 39
• Textbook of Family Medicine 9e
• Murray & Nadel's Textbook of Respiratory Medicine

Comparison with Key Differentials

Recent Evidence